Tumor Thrombosis
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis (NCT06389422) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-05-01 |
| Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis (NCT06233981) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-25 |
Track Tumor Thrombosis automatically
Every clearance here is in the API, with alerts when new ones post.